In the Altai Krai, the development of pharmaceutical industry and biotechnology is aimed at ensuring import substitution of medicinal products by their Russian-made analogs.
According to the Altay Krai statistical agency, in January-December 2016, the volume of manufactured medicinal products amounted to 105.0% compared to the corresponding period of previous year. The companies shipped pharmaceutical products worth 3.61 billion rubles, which is 113.9% compared to the corresponding period of previous year.
Most of the products (67%) manufactured by companies of biopharmaceutical cluster are sold in other Russian regions, and about 14% are exported abroad.
In 2016, the participants of Altai Biopharmaceutical Cluster shipped products worth more than 20 billion rubles. For some companies, the output growth reached 35%.
The participants of Altai Biopharmaceutical Cluster increase their investment activities, expand their sales markets, and develop innovative products. The largest companies participating in the partnership, including Altaivitaminy CJSC and Evalar CJSC, continued to implement their investment projects aimed at developing the advanced manufacturing base that meets GMP standards, manufacturing and launching new medicinal products, developing and manufacturing biologics.